RBR-5f6qjg进行中（未招募）3 期
A Phase 3, Randomized, Double-blinded Study of IMC-1121B and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First-line Platinum- or Fluoropyrimidine-Containing Combination Therapy
ImClone Systems Incorporated0 个研究点开始时间: 2013年1月2日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Intervention
入排标准
- 年龄范围
- 18Y 至 —（—）
入选标准
- •Histologically or cytologically confirmed gastric carcinoma, including gastric adenocarcinoma or Gastroesophageal Junction (GEJ) adenocarcinoma; metastatic disease or locally recurrent; unresectable disease with measurable lymph node metastases; measurable disease and/or evaluable disease. ; experienced disease progression during or within 4 months after the last dose of first-line therapy for metastatic disease, or during or within 6 months after the last dose of adjuvant therapy; disease not amenable to potentially curative resection; patient is over 18 years old; there is no maximum age for enrollment in the study; patient has a life expectancy of 12 or more weeks; patient resolution to Grade = 1 (or to Grade = 2 in the case of neuropathy) by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.02, of all significant toxic effects of prior chemotherapy, surgery, radiotherapy, or hormonal therapy (with the exception of alopecia); Eastern Cooperative Oncology Group Performance Status score of 0-1; adequate hepatic function; adequate renal function; urinary protein is = 1+ on dipstick or routine urinalysis; adequate hematologic function; adequate coagulation function. ; if the patient has received prior anthracycline therapy as part of his or her first-line regimen, the patient is able to engage in ordinary physical activity without significant fatigue or dyspnea; patient, if sexually active, must be postmenopausal, surgically sterile, or using effective contraception (hormonal or barrier methods); female patients of childbearing potential must have a negative serum pregnancy test within 7 days prior to randomization; able to provide informed written consent and is amenable to compliance with protocol schedules and testing.
排除标准
- •Brain or leptomeningeal metastases. Experienced any Grade 3-4 gastrointestinal bleeding within 3 months prior to randomization; experienced any arterial thromboembolic events within 6 months prior to randomization; ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, symptomatic or poorly controlled cardiac arrhythmia, uncontrolled thrombotic or hemorrhagic disorder, or any other serious uncontrolled medical disorders in the opinion of the investigator; ongoing or active psychiatric illness or social situation that would limit compliance with study requirements; uncontrolled or poorly-controlled hypertension; patient has a serious or nonhealing wound, ulcer, or bone fracture. Received chemotherapy, radiotherapy, immunotherapy, or targeted therapy for gastric cancer within 2 weeks prior to randomization; received any investigational therapy within 1 year prior to randomization; undergone major surgery within 28 days prior to randomization, or subcutaneous venous access device placement within 7 days prior to randomization; received prior therapy with an agent that directly inhibits VEGF or VEGFR-2 activity, or any antiangiogenic agent. Receiving chronic antiplatelet therapy; known allergy to any of the treatment components; pregnant or lactating; known to be positive for infection with the human immunodeficiency virus; known alcohol or drug dependency; concurrent active malignancy other than adequately-treated nonmelanomatous skin cancer, other noninvasive carcinoma, or in situ neoplasm; patient with previous history of malignancy is eligible, provided that he/she has been free of disease for > 3 years.
研究者
相似试验
已完成
3 期
A clinical trial to study the effects of IMC-1121B and best supportive care (BSC) versus Placebo and BSC in patients with metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first line care.CTRI/2010/091/001245ImClone LLC348
进行中（未招募）
不适用
Study investigating new drug, IMC-1121B, in patients with advanced cancer of the stomach/oesophagus that has grown despite standard chemotherapy (combination of chemotherapy including platinum or fluoropyrimidine). Study has two arms. Patients will be assigned randomly to either arm: Arm1: 2/3 of patients receive IMC-1121B and best supportive care; Arm2: 1/3 receive an inactive substance (placebo) and best supportive care. Neither the patient nor the doctor will know the treatment arm.EUCTR2008-005964-15-CZImClone LLC348
进行中（未招募）
不适用
A Phase 3, Randomized, Double-Blinded Study of IMC-1121B and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First-Line Platinum- or Fluoropyrimidine-Containing Combination Therapy - NDEUCTR2008-005964-15-ITIMCLONE LLC615
进行中（未招募）
1 期
Study investigating new drug, IMC-1121B, in patients with advanced cancer of the stomach/oesophagus that has grown despite standard chemotherapy (combination of chemotherapy including platinum or fluoropyrimidine). Study has two arms. Patients will be assigned randomly to either arm: Arm1: 2/3 of patients receive IMC-1121B and best supportive care; Arm2: 1/3 receive an inactive substance (placebo) and best supportive care. Neither the patient nor the doctor will know the treatment arm.Metastatic Gastric CancerMedDRA version: 14.1 Level: PT Classification code 10063916 Term: Metastatic gastric cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-005964-15-GBImClone LLC355
进行中（未招募）
1 期
Study investigating new drug, IMC-1121B, in patients with advanced cancer of the stomach/oesophagus that has grown despite standard chemotherapy (combination of chemotherapy including platinum or fluoropyrimidine). Study has two arms. Patients will be assigned randomly to either arm: Arm1: 2/3 of patients receive IMC-1121B and best supportive care; Arm2: 1/3 receive an inactive substance (placebo) and best supportive care. Neither the patient nor the doctor will know the treatment arm.Metastatic Gastric CancerMedDRA version: 15.1Level: PTClassification code 10063916Term: Metastatic gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-005964-15-MTImClone LLC355